Polatuzumab Vedotin Combined With R-ICE (PolaR-ICE) as Second-Line Therapy in Diffuse Large B-Cell Lymphoma - PubMed
5 hours ago
- #Autologous Stem Cell Transplant
- #DLBCL
- #Polatuzumab Vedotin
- Polatuzumab Vedotin combined with R-ICE (PolaR-ICE) evaluated as second-line therapy for relapsed/refractory diffuse large B-cell lymphoma (DLBCL).
- Study aimed to improve complete response rates and post-autologous stem cell transplantation (ASCT) outcomes.
- 41 patients treated with PolaR-ICE showed an overall response rate of 88% and complete response rate of 56%.
- 56% of patients proceeded to ASCT, with 39% receiving Pola consolidation therapy.
- At median follow-up of 25 months, 2-year progression-free survival (PFS) was 49.9% and overall survival (OS) was 75.0%.
- Patients relapsing ≤12 months after initial therapy had lower 2-year PFS (36.4%) compared to those relapsing ≥12 months (80.0%).
- PolaR-ICE found to be a safe and effective salvage regimen, particularly for late relapses or areas with limited CAR T-cell therapy access.